Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:1231-1232 (16 December), doi:10.1136/bmj.39059.444120.80
The art of being all things to all people
| The first 150 words of the full text of this article appear below. |
Prompted by concern that the drug industry might reduce its investment in research in the United Kingdom, the chancellor of the exchequer asked the distinguished venture capitalist Sir David Cooksey to lead a review. Widespread consultation showed that it is not only the Treasury that is concerned about the current state of health research funding, organisation, and performance.1
Four principal criticisms emerged. Firstly (confirming the Treasury's view), the drug industry is frustrated by what it sees as increasing obstacles to gaining access to patients and over-regulation leading to unacceptable delays and extra costs. Companies claim that developing products and conducting research in other countries is increasingly attractive and an inevitable consequence. Secondly, those responsible for providing health servicespoliticians, managers, cliniciansas well as research funders are concerned at the delays in translating advances in basic science into clinical applications and then translating such innovations into routine practice. This is seen as
Nick Black, professor of health services research (Nick.Black@lshtm.ac.uk)
1 London School of Hygiene and Tropical Medicine, London WC1E 7HT
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.